ArticleJournal of medical case reports2025
Induction hepatic arterial infusion chemotherapy followed by surgery for hepatocellular carcinoma with massive portal vein tumor thrombosis: a case series of 20 patients.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of hepatocellular carcinoma with portal vein tumor thrombosis is very poor, and the optimal treatment remains controversial. The aim of this study is to examine the safety and feasibility of our multimodal treatment.
methodsThis was a single-institution, retrospective case series. From 2013 to 2018, induction hepatic arterial infusion chemotherapy was given to 20 consecutive Japanese patients with hepatocellular carcinoma harboring portal vein tumor thrombosis in the main portal trunk or first branch, even with intrahepatic and extrahepatic metastasis. When the cancers including thrombus and metastatic disease were well controlled, surgical resection was considered. When macroscopic complete resection was achieved, two courses of hepatic arterial infusion chemotherapy were added as adjuvant therapy, whereas patients who had remnant disease after surgery were provided treatment according to the type of lesion.
resultsNo treatment-related deaths were noted. The objective response rate and disease control rate were 35.0% and 65.0%, respectively. After induction treatment, 10 of 20 patients underwent surgery. Postoperative complications (Clavien-Dindo grade III or more) were observed in three cases, and median postoperative hospital stay was 15.5 days. Median survival time of all 20 patients was 14.5 months and that in patients who underwent surgery was significantly longer than that in patients with unresectable hepatocellular carcinoma (19.5 months versus 9.0 months, p = 0.0018).
conclusionInduction treatment followed by surgery was safe and feasible for hepatocellular carcinoma with massive portal vein tumor thrombosis. Surgical resection might be oncologically appropriate for selected patients after induction treatment even with advanced stage hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.